Literature DB >> 32705737

Obstructive sleep apnea syndrome in patients with chronic idiopathic urticaria.

Emine Tugba Alatas1, Yasemin Unal2, Suzan Demir Pektas1, Gulnihal Kutlu2.   

Abstract

Urticaria is a disease which progresses with itchy papules and plaques called urtica, obstructive sleep apnea syndrome (OSAS) is defined as daytime sleepiness and obstructive apnea and hypopnea attacks during sleep. In this study, we aimed to investigate the relationship between urticaria and OSAS. Thirty-one patients with chronic idiopathic urticaria were included in the study. Body mass indexes (BMIs) were calculated and polysomnography findings were recorded. Epworth Sleepiness Scale and Pittsburgh Sleep Quality Index were used to evaluate daytime sleepiness. The prevalence and severity of urticaria were calculated using the urticaria activity score (UAS). Chronic Urticaria Quality of Life Questionnaire was applied to patients. OSAS was detected in 13 (41.9%) of 31 patients. Then, 11 of the 13 patients had mild, 1 had moderate, and 1 had severe OSAS in the patient group. OSAS was not detected in the control group. A positive correlation was found between apnea-hypopnea index and BMI, the UAS scores in the patient group (respectively, r = .537, P = .002, r = .407, P = .023). In this study, we found that the frequency of OSAS in patients with urticaria was more than that in the normal population. Doctors treating urticaria should consider a comorbidity disease such as OSAS and regulate the treatment according to these two diseases.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  inflammatory disease; urticaria

Mesh:

Year:  2020        PMID: 32705737     DOI: 10.1111/dth.14060

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  2 in total

1.  "Chronic urticaria and obstructive sleep apnea: Is there a significant association?"

Authors:  Ivan Cherrez-Ojeda; Marcus Maurer; Miguel Felix; Jonathan A Bernstein; German D Ramon; Roberta Fachini Jardim Criado; Valeria L Mata; Annia Cherrez; Blanca María Morfin-Maciel; José Ignacio Larco; Iván O Tinoco; Gonzalo Federico Chorzepa; René Maximiliano Gómez; Rodolfo Jaller Raad; Simon Francis Thomsen; Peter Schmid-Grendelmeier; Carole Guillet; Sofia Cherrez; Emanuel Vanegas
Journal:  World Allergy Organ J       Date:  2021-08-24       Impact factor: 4.084

2.  Ligelizumab improves sleep interference and disease burden in patients with chronic spontaneous urticaria.

Authors:  Ana Giménez-Arnau; Marcus Maurer; Jonathan Bernstein; Petra Staubach; Nathalie Barbier; Eva Hua; Thomas Severin; Yolandi Joubert; Reinhold Janocha; Maria-Magdalena Balp
Journal:  Clin Transl Allergy       Date:  2022-02       Impact factor: 5.871

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.